Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is:
- To determine whether it is feasible in locally advanced gastric or gastroesophageal
cancer to administer 3 cycles of Docetaxel, Oxaliplatin and S-1 as a chemotherapy scheme
and also to determine what toxicities are involved.
The secondary objective of this trial are to describe:
- The disease free survival at one and two years in that subgroup of patients that has
undergone a R0 resection.
- The downstaging after 3 cycles of chemotherapy, pCR in that subgroup of patients that
have undergone an R0 resection and progression-free survival and overall survival at one
and two years.